Maria J. Redondo is a Professor at Baylor College of Medicine and leads the Maria J. Redondo Lab at Texas Children’s Hospital, focusing on Type 1 Diabetes across four core areas: Genetics for prediction models and trial candidate selection Heterogeneity in diabetes pathogenesis Prevention through clinical trials Atypical Diabetes and Racial/Ethnic Influences Research Trends: Her recent articles emphasize genetic risk modeling, BMI correlations in pediatric diabetes, and HLA studies. The work integrates autoimmunity , metabolic research , and epidemiological analysis . Scientific Awards: Elected to the Society for Pediatric Research (2014) JDRF Early Career Development Award (2002) JDRF Postdoctoral Fellowship (2000) Immunology of Diabetes Society Junior Investigator Award (1998) Mentoring: Dr. Redondo mentors fellows and students in projects like COVID-19 and Diabetes and Racial Differences in Insulin Pump Uptake , with grants from NIH , Medtronic , and Hemsley Charitable Trust .
Angela Di Fulvio is an Associate Professor and Donald Biggar Willett Faculty Scholar at the University of Illinois at Urbana-Champaign, holding joint appointments in the Department of Nuclear, Plasma, and Radiological Engineering and the Center for Digital Agriculture at NCSA. She leads the Nuclear Measurement Laboratory (NML), focusing on radiation detection technologies for nonproliferation, medical physics, and nuclear security. Her academic journey includes a Ph.D. in Nuclear Engineering and Industrial Safety from the University of Pisa (2012), preceded by M.Sc. and B.Sc. degrees in Bioengineering. Her research emphasizes neutron detection instrumentation, radiation protection in therapy, and safeguards applications. Key areas include next-generation thermal neutron detectors, boron neutron capture therapy dosimetry, and spent nuclear fuel imaging. She has pioneered work on pulse shape discrimination using commercial ASICs and developed algorithms for neutron-gamma discrimination in harsh environments. Di Fulvio’s 15+ peer-reviewed articles span advanced detection systems, Monte Carlo modeling, and machine learning for radiation imaging. Notable contributions include a physics-based forward model for spent fuel imaging and variational autoencoder-based pulse discrimination. Her work has been recognized with the Dean’s Award for Excellence in Research. Professional roles include Associate Editor of Radiation Measurements and editorial board member of Nature Scientific Reports . She chairs APS’s Instrumentation and Measurement Science group and ANS’s Nuclear Nonproliferation Policy Division. Recent courses taught include NPRE 451-452 labs, Nuclear Safeguards, and Student Research Seminars.
Joseph P. Bressler is an Associate Professor at Johns Hopkins University, jointly affiliated with the Bloomberg School of Public Health and the Krieger School of Arts and Sciences. He is a member of the Department of Environmental Health and Engineering and conducts research at the Kennedy Krieger Institute in Baltimore, Maryland. His work bridges public health, neuroscience, and molecular toxicology, focusing on environmental impacts on brain development. Education: PhD, Rutgers University, 1978 Dr. Bressler’s research centers on neurotoxicology, particularly how environmental pollutants such as lead, cadmium, and aluminum disrupt metal transport systems and affect neurodevelopment. His laboratory investigates the role of iron and other metal transporters at the blood-brain barrier and in glial cells, revealing mechanisms of metal uptake and toxicity. His work has implications for understanding autism, fetal alcohol syndrome, and other neurodevelopmental disorders. His recent publications highlight ongoing research into metal homeostasis, cytotoxicity in cancer and neuronal cell lines, e-cigarette aerosol variability, and epigenetic changes in sex chromosome aneuploidies. The research spans molecular mechanisms, in vitro models, and human health outcomes, demonstrating a multidisciplinary approach to environmental health. Scientific Contributions: Elucidated how lead and cadmium hijack iron transporters to enter the brain Demonstrated aluminum activation of iron uptake pathways in glial cells Investigated flavoring agents like ethyl maltol in enhancing metal toxicity Explored epigenetic and behavioral impacts in rare genetic conditions Dr. Bressler has advised numerous researchers and collaborators across disciplines. His work has been supported by federal and institutional grants, though specific funding details are not provided in the source text. He actively publishes in high-impact toxicology and environmental health journals, with research cited in policy and public health discussions. He leads a research laboratory focused on cellular and molecular mechanisms of neurotoxicity, utilizing in vitro models of the blood-brain barrier, astrocytes, and neuronal cell lines. His team collaborates widely across neuroscience, public health, and environmental engineering domains.
Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Prof. Friederike Ebner holds the Chair of Infection Pathogenesis at the Technical University of Munich (TUM) since 2023, within the TUM School of Life Sciences. Her research focuses on the immunobiology of parasite infections, particularly studying gastrointestinal helminths like Ascaris suum and their interactions with host immune systems to design novel intervention strategies. She also develops biomedical models for studying infectious diseases. Educational Background: Friederike Ebner earned a biotechnology degree from TU Berlin and Dongseo University (South Korea). She completed her PhD in biology at Humboldt University Berlin (2014), followed by postdoctoral research in immunology at Freie Universität Berlin, where she became an assistant professor before moving to TUM. Research Interests: Her work spans helminth-host immune dynamics, vaccine development, microbiome interactions in parasitic infections, and translational models for human diseases. Key topics include Th2/Th1 immune balance, helminth-derived immunomodulators, and xenotransplantation safety. Notable Contributions: Her recent studies address diagnostic methods for ascariasis, microbiome roles in helminth survival, and immunotherapeutic applications of parasite products. Current efforts emphasize bridging fundamental immunology with clinical and veterinary applications. Professional Activities: Prof. Ebner teaches immunology and parasite biology at TUM while maintaining active collaborations in global health and infectious disease research. She advocates for interdisciplinary approaches to address knowledge gaps in parasitology and vaccinology.
Thomas Winkler is an Associate Professor at the Division of Micro and Nanosystems, KTH Royal Institute of Technology, Sweden, and collaborates with TU Braunschweig, Germany. His research focuses on solving life science challenges using microsystems tools, particularly in neuropsychiatric disorders like schizophrenia. He develops organ-on-chip models, engineered microfluidic platforms, and biosensors for point-of-care diagnostics. Winkler leads an interdisciplinary ERC-funded team addressing metabolic coupling in neurovascular units and oxidative stress biomarkers. Key achievements include the ERC Starting Grant (2023) and work on electrochemical sensors for clozapine monitoring. He teaches courses such as Microsystem Technology (EK2350) and supervises PhD and postdoctoral researchers. Current projects include machine learning-guided robotic organoid maturation and electrochemical technology development for the CHIPzophrenia initiative. His lab actively seeks talent through open positions in Stockholm and Braunschweig. Scientific awards include the ERC Starting Grant and Marie Skłodowska-Curie Actions Fellowship. Research spans sensor development, microfabrication, and biomaterials, with a focus on translating lab technologies to clinical applications. Collaborations bridge engineering and life sciences, emphasizing personalized mental healthcare solutions.
Thomas Lectka is the Jean and Norman Scowe Professor in the Department of Chemistry at Johns Hopkins University, where he has been a faculty member since 1994. His research focuses on synthetic and physical organic chemistry, particularly in the area of organofluorine chemistry. PhD, Cornell University Postdoctoral Fellow, Heidelberg (Alexander von Humboldt Fellow) Postdoctoral Fellow, Harvard University (NIH Fellow) Dr. Lectka's research is centered on developing novel synthetic methods, especially for fluorination, and understanding the physical organic principles underlying reactivity. His work spans radical fluorination , catalytic asymmetric synthesis , and the design of fluorinated bioactive molecules . Using a combination of experimental and computational techniques, his lab investigates C-F bond formation , reaction mechanisms , and the biological applications of fluorinated compounds. His recent work, as reflected in publications from 2010 to 2024, shows a consistent trajectory in advancing fluorination methodologies, with increasing emphasis on site-selectivity , enantiocontrol , and biomedical relevance . Themes include the development of new reagents, mechanistic studies, and the synthesis of fluorinated natural product analogs and peptidomimetics. Dr. Lectka has received numerous honors and awards, including: ACS Arthur C. Cope Scholar (2024) ACS Maryland Chemist of the Year (2017) John Simon Guggenheim Memorial Fellowship Dreyfus Teacher-Scholar Award Sloan Fellowship NSF CAREER Award NIH First Award Eli Lilly Grantee Award He actively mentors graduate and undergraduate students in his research group, contributing to education and training in organic chemistry. His lab, The Lectka Group , is supported by grants from the NIH and NSF, enabling cutting-edge research in synthetic methodology and physical organic studies. The group fosters a collaborative environment focused on innovation in fluorine chemistry. The Lectka Group is an active research laboratory at Johns Hopkins University dedicated to pushing the boundaries of synthetic organic chemistry through the exploration of fluorine's unique properties. Current projects include site-selective radical fluorination and the synthesis of unusual fluorinated species, aiming to provide new tools for drug discovery and materials science.
Prof. dr. Tessa Quax is an Associate Professor at the Faculty of Science and Engineering, University of Groningen, leading research in Molecular Microbiology . Her work focuses on archaeal virology and virus-host interactions, supported by prestigious grants including an ERC Starting Grant (2022) and NWO Vidi Grant (2023). Key Research Areas: Archaeal virus entry/egress mechanisms Cell surface dynamics and motility Extreme environment microbiology Genetic tool development for archaea Recent publications in Nature Reviews Microbiology (2025) and Current Opinion in Microbiology (2024) highlight her work on viral host recognition and structural diversity. Her lab's 44 research outputs span archaeal cell biology, viral evolution, and ecological impacts of virus-induced lysis. Scientific Recognition: KNAW Beijerinck Premium (2022) KNAW Early Career Award (2021) Hector Research Career Development Award (2021) ERC Starting Grant (2022) As Chair of the International Society for Viruses of Microbes SAB and Speaker of the German Microbiology Society's Microbial Viruses group, she coordinates global research networks including a HFSP grant (2023) with Japan/Australia/USA collaborators. Her lab currently includes PhD candidate Zaloa Aguirre Sourrouille and multiple postdoctoral researchers.
Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.
Steven A. Soper is a Foundation Distinguished Professor in the Department of Chemistry and Mechanical Engineering at the University of Kansas. He serves as Director of the NIH-funded Center for BioModular Multi-Scale Systems for Precision Medicine and leads international collaborations with institutions like UNIST in South Korea. His career spans faculty roles at LSU, UNC, and KU, with interdisciplinary research bridging chemistry, biomedical engineering, and materials science. Ph.D. in Bioanalytical Chemistry, University of Kansas (1989) Postdoctoral Fellow, Los Alamos National Laboratory (1991) B.S. in Chemistry and Psychology, University of Nebraska (1980-1982) Research Interests focus on micro-/nanofabricated biochemical analysis systems for clinical diagnostics, particularly circulating tumor cell analysis , cell-free DNA detection , and single-molecule fluorescence applications. His work integrates polymer microfabrication, FRET-based assays, and thermoplastic nanofluidics for cancer, stroke, and infectious disease diagnostics. Scientific Awards include: R&D 100 Award (2010) Shannon Award (NIH) (1994) Distinguished Research Master, LSU (2002) Fellow, AAAS/RSC/SAS (2010) Sutton Family Research Impact Award (2021) Teaching & Collaboration involves mentoring 39 professional-degree recipients, organizing multidisciplinary research teams, and co-teaching courses in Biofluid Mechanics and Nanotechnology . His lab partners with institutions in South Korea and UNC/NCSU, while hosting international students and professionals. Labs & Centers : Leads the Soper Research Group and the Center for BioModular Multi-Scale Systems , which provides access to state-of-the-art nanofabrication tools and collaborative expertise across 12 institutions.
Cagri A. Savran is a Professor of Mechanical Engineering at Purdue University, with courtesy appointments in Biomedical Engineering and Electrical and Computer Engineering. He holds a B.S. from Purdue University (1998), an M.S. and Ph.D. from MIT (2000 and 2004, respectively). His research focuses on MEMS, nanotechnology, and biosensors, particularly in protein detection, aptamers, and biomedical applications. His work spans fluid mechanics, systems control, and micro/nano fabrication. Education: B.S., Purdue University, 1998 M.S., MIT, 2000 Ph.D., MIT, 2004 Research Interests: Dr. Savran pioneers innovations in bioMEMS and nanoscale biosensing technologies. His lab develops platforms like immunomagnetic diffractometry and microfluidic systems for real-time pathogen detection and clinical diagnostics. Key areas include aptamer-based assays, magnetic nanoparticle integration, and single-molecule studies of DNA packaging motors. Awards: Motorola PhD Fellowship (2001-2004) NSF U.S.-Japan Young Researchers Exchange (2007) #1 News in Analytical Chemistry (2007) #1 News in JACS Weekly (2007) Labs & Teams: The Savran Lab (savranlab.org) integrates engineering and biology to create next-generation biomedical devices. Research emphasizes translating nanotechnology into practical diagnostic tools for healthcare and environmental monitoring.
Jeffrey T. Jensen, M.D., M.P.H., is the Leon Speroff Professor and Vice Chair for Research in the Department of Obstetrics and Gynecology at Oregon Health & Science University (OHSU). He holds joint appointments as Professor of Public Health and Preventive Medicine and serves as a Core Scientist at the Oregon National Primate Research Center (ONPRC). Dr. Jensen completed his medical degree at Emory University, a Master of Public Health at the University of Washington, and residency training at OHSU. Research Focus: Dr. Jensen leads translational and clinical research programs focused on contraceptive innovation. His work emphasizes nonhuman primate models to develop: Novel contraceptive agents targeting oocyte-specific pathways Non-surgical permanent contraception methods Optimized emergency contraception for diverse populations He directs OHSU's Women’s Health Research Unit and the Gates Foundation-funded Oregon Permanent Contraception Research Center (OPERM). Recent Publications: His 15 most recent articles (2023-2025) demonstrate concentrated expertise in: Advanced hormonal contraceptive formulations (IUDs, vaginal rings, oral agents) Weight-adjusted dosing strategies for emergency contraception Biomarker validation for contraceptive efficacy monitoring Real-world assessment of bleeding pattern management Leadership & Collaboration: Dr. Jensen is Principal Investigator of the NICHD Contraception Clinical Trials Network and collaborates with global health organizations (CONRAD, FHI360, Population Council). He serves as Deputy Editor for the journal Contraception and consults for multiple pharmaceutical companies on product development.
Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.
Pere Roca-Cusachs Soulere is a Full Professor at the University of Barcelona and Group Leader at the Institute for Bioengineering of Catalonia (IBEC). His research focuses on understanding how cells detect and respond to mechanical signals through physical and molecular mechanisms. He holds significant roles in both academic and research institutions, including leadership in IBEC's Cellular and Molecular Mechanobiology group. Education: PhD in cellular biophysics (2007) from the University of Barcelona Medical School; postdoctoral research at Columbia University (2007–2011). Established his group at IBEC in 2012. Awards include the EMBO Young Investigator Award, City of Barcelona Award, and EBSA Young Investigator Award. Research Interests: Mechanobiology, cellular mechanotransduction, force transmission, nuclear mechanics, and integrin-mediated adhesion. His work bridges biophysics, cell biology, and engineering to study how mechanical forces influence cellular behavior and disease processes. Awards: Recognized for contributions to mechanobiology, including EMBO membership and multiple prestigious awards. His lab develops innovative tools like the MIRO chip to model tumor-immune interactions. Advising & Grants: Leads a multidisciplinary team, collaborating on projects funded by grants focusing on cell mechanics, cancer biology, and tissue engineering. His work integrates experimental and computational approaches to advance understanding of cellular force dynamics. Labs/Teams: Directs the Cellular and Molecular Mechanobiology group at IBEC, a hub for cutting-edge research on mechanosensing and mechanotransduction.
